Functional biomarkers are objective measurements that reflect the process and progression of a disease, and the effect of drug intervention. They enable everything from earlier, more accurate disease ...

Sometimes, companies discover they need a biomarker – and an IVD development partner – relatively late in the development process. In such cases, one option is to leverage an existing relationship ...

The FDA and the EMEA are testing a Pilot Process for Biomarker Qualification, which was created based on the specific need for new biomarkers in drug development. This Pilot Process needs to be tested ...

Early and accurate diagnosis is a priority in improving treatment response and in slowing down neurodegeneration and disease progression, regardless of outstanding advancements in therapeutics. Recent ...

While the use of precision therapies continues to expand, precision oncology drug development is facing increasing costs and complexity. In today's biomarker-driven landscape, it is more important ...

The Prognostic Lung Fibrosis Consortium (PROLIFIC), a collaborative consortium advancing biomarker tools for pulmonary ...

KineMed, Inc. has announced a further award of $1.2 Million from The Michael J. Fox Foundation towards the ongoing development of kinetic biomarkers that drug developers can use to accelerate and ...